allowing the differentiation of PSCP from papillary serous ovarian carcinoma [4] , which has similar histological aspect but different prognosis [5] . Ovarian serous tumors are generally discovered after spreading into the peritoneal surfaces; they are arbitrarily assigned to the ovary when involvement of this organ overtakes 5 mm [6] . This observation supports the hypothesis that papillary serous ovarian carcinoma originates from the epithelium NobleResearch www.nobleresearch.org of the peritoneal cavity and secondary involves the ovarian tissue [7, 8] .
Case presentation
We present a case report of a 47-year-old woman who was admitted to our University-Hospital following diagnosis of pelvic mass. She suffered from gastrointestinal symptomatology, observing alteration of bowel habit consisting in constipation alternated with diarrhea and associated with discomfort on the left iliac region. Abdominal examination revealed a tender, palpable mass on the right iliac region. At the gynecological examination uterus was regular in size. On the left side of the uterus a mass of 9 cm was observed; its surface was irregular and no mobility was found. The mass was painful during palpation and it compressed both sigmoid colon and rectum. Right ovary was regular in size and fix.
Initial routine blood tests showed 14.97 g/dl of hemoglobin, normal mean cell volume and no abnormalities of electrolytes, liver or kidney function were observed. Tumor markers revealed an increase of CA125:47,02 U/ml and CA 15-3: 61,15 U/ml, whereas CA 19-9 was normal ( 3 U/ml ). Abdominal CT and NMR revealed massive ascites, omental cake and increased volume of both ovaries.
Patient underwent longitudinal suprombelical-pubic laparotomy. After opening abdominal cavity, a freefluid sample was taken and the results were positive for malignant cells. Typical neoplastic localizations on both ovaries, Douglas' peritoneum, rectum, sigmoid colon and omentum were observed.
Extemporaneous histological examination diagnosed a peritoneal serous papillary carcinoma. Hysterectomy with salpingo oophorectomy (Figure 1 ), total omentectomy, appendectomy, pelvic and lumbo-aortic lymphadenectomy were performed. Surgeons chose retroperitoneal approach in order to remove the Douglas' peritoneum together with the pouch malignant localizations. Sigmoid colon and rectum were resected ( Figure 2) . A latero-terminal anastomosis with stapler was performed ( Figure 2 ). After opening the rectum a crateriform lesion was observed (Figure 3) . Finally, all the visible abdominal maligant lesions were cut out. No transfusion was necessary. The postoperative course was regular and after seven days the patient was discharged. Final histological examination was not able to establish if the ovarian lesions were primary or secondary to a peritoneal extra ovarian serous carcinoma. Chemotherapy ended the therapeutic management (six cycles of carboplatin and paclitaxel). After one year the patient is in good health and instrumental investigations (Ultrasounds, TC and NMR) are negative for recurrence. 
Discussion
Management of PSPC is similar to ovaric neoplasms, although prognosis should be worse. Long-term survival has been described with cytoreductive surgery and adjuvant chemotherapy with platinum. Surveillance remains the best course of management for patients with known BRCA gene mutations, particularly.
Similar to the epithelial ovarian cancer [9] , a high percentage of women with PSCP were diagnosed in an advanced stage, in spite of the aggressive nature of this lesion.
PSCP is diagnosed in the presence of a large, generally disseminated, tumor mass involving peritoneal surfaces with minimal or nonexistent tubal and ovarian involvement [10, 12] . High-grade serous carcinomas, characterized by genetic instability and TP53 mutations, are thought to arise in the fallopian tube mucosa or the mullerian epithelium involving the peritoneum and the ovary secondarly [7, 8] .
The tubal fimbria, which is close to the ovarian surface and exposed to the peritoneal cavity, has been identified as one of the most common sites of early serous carcinoma for BRCA-positive women [11] .
Conclusion
This case report offers the topic of some consideration as follows: (1) Difficulty of diagnosis, (2) Surgical treatment, (3) Adjuvant chemotherapy.
As for as the clinic diagnosis, initial peritoneal cancer does not give specific symptoms and, accordingly, it is hard to detect in the early stages. That's because its symptomatology is vague. When clear symptoms occur, the disease has progressed. Then, symptoms resemble those of ovarian cancer. Many of these symptoms are a consequence of fluid increase (ascites) in abdominal cavity. Peritoneal cancer symptoms may include: PSPC is often detected when lesion involves many organs. In such cases, it is difficult to detect the true origin even when sophisticated imaging techniques (US, TC, NMR) are employed. Besides, final histological examination may be not able to establish if the lesions of peritoneal sheet are either primary or secondary, as it happened in this case report.
Regarding the surgical treatment, the operation plays a very important role and affects the prognosis predominantly. During surgery, the removal of all malignant lesions offers a better life expectancy. Collaboration between gynecological and surgical team is mandatory.
The operation needs a very great effort. Regarding the specific technique we must emphasize that retroperitoneal approach offers the advantage of removing the parietal peritoneum together with the intra-abdominal lesions; nevertheless its execution is challenging and requires surgical expertise. As regards the adjuvant chemotherapy, it is important for the whole management of disease. Chemotherapy employs anti-cancer (cytotoxic) drugs to destroy malignant cells. Both PSPC and ovarian cancer are usually very sensitive to chemotherapy. Chemotherapy is usually given after surgery to reduce the risk of the malignant recurrence. It also may help reduce the extent of the lesions before surgery and facilitate the subsequent surgery. Most women with ovarian cancer have several cycles (an average of six) of chemotherapy as an outpatient, with rest periods in between. Moreover we must not forget that chemotherapy has side effects such as tiredness, hair loss and lowered immunity, although some can be controlled with suitable drugs. The most commonly used drug is carboplatin, which may be given with paclitaxel (Taxol). Some other drugs that are less commonly used, or may be used if the cancer comes back, are: topotecan, liposomal doxorubicin, cisplatin, docetaxel, gemcitabine and etoposide. Finally, a correct anatomical definition of both nature and grading together with the evolution of the malignant disease is compulsory for an appropriate management and therapy [12] . Such a case is very interesting for the discrepancy between slight symptoms and severity of the disease, the solution of which was very complex requiring a skillful polyspecialized oncological team.
